Skip to navigation Skip to content



MS Trial Alert: Investigators Recruiting for Two Phase 3 Trials of Experimental Fenebrutinib in Relapsing MS

September 14, 2022

SUMMARY:  Investigators in the U.S. and abroad are recruiting a total of 1468 people with relapsing forms of MS for two separate studies comparing investigational oral fenebrutinib with Aubagio® (teriflunomide, Sanofi Genzyme). The studies – also called FENhance – are sponsored by F. Hoffmann-La Roche.

Rationale: Fenebrutinib inhibits an enzyme called “Bruton’s tyrosine kinase,” reducing the activation of B cells, which are immune cells that play a role in the response that affects the brain and spinal cord in MS. Fenebrutinib also inhibits immune cells in the brain called microglia, which have been linked to MS progression. Fenebrutinib is one of several “BTK” inhibitors being tested in clinical trials involving people with different types of MS.

Eligibility and Details: Participants should be 18 to 55 years old, and diagnosed with relapsing forms of MS, which include relapsing-remitting disease and active secondary progressive disease (with relapses).  Other criteria may apply.

In both studies, participants will be randomly assigned to daily treatment with fenebrutinib and a placebo matching Aubagio, or daily treatment with Aubagio and a placebo matching fenebrutinib, for a treatment duration of 96 weeks. The primary outcome of both studies will compare how treatment affects the annual rate of relapses. Secondary outcomes include disability worsening, disease activity on MRI scans, physical function, cognition, and safety.

What Else is Involved? The study involves up to 20 in-person visits each to the study site. Visits will involve MRI scans, blood draws, clinical exams, and responding to questionnaires. Patients who complete this phase may be eligible to enter an open-label extension phase for 96 weeks, during which all participants will receive fenebrutinib.

Please note: This study requires in-person visits to the study site. Precautions are being taken to reduce the on-site risks of exposure to COVID-19.
Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please visit the study website at, call 888-662-6728 or email

In the U.S., sites are enrolling in the following cities:
Cullman, AL
Homewood, AL
Phoenix, AZ
Tucson, AZ
Carlsbad, CA
Irvine, CA
Orange, CA
Palo Alto, CA
Pasadena, CA
Torrance, CA
Aurora, CO
Basalt, CO
Denver, CO
Fort Collins, CO
Glenwood Springs, CO
Stamford, CT
Boca Raton, FL
Maitland, FL
Miami, FL
Tampa, FL
Evanston, IL
Avon, IN
Fort Wayne, IN
Kansas City, KS
Baton Rouge, LA
Foxboro, MA
Worcester, MA
Detroit, MI
Owosso, MI
Newark, NJ
Teaneck, NJ
Potsdam, NY
Canton, OH
Centerville, OH
Cincinnati, OH
Columbus, OH
Dayton, OH
Dublin, OH
Oklahoma City, OK
Portland, OR
Bethlehem, PA
Danville, PA
Pittsburgh, PA
Greer, South Carolina
Cordova, TN
Knoxville, TN
Georgetown, TX
Houston, TX
Round Rock, TX
Sherman, TX
Christiansburg, VA
Falls Church, VA
Roanoke, VA
Vienna, VA
Kirkland, WA
Tacoma, WA
Milwaukee, WI
Washington D.C.

Download a brochure that discusses issues to think about when considering enrolling in an MS clinical trial (PDF).
Without participants in research studies, MS research would come to a standstill. Read more here.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.